Thanks Biotechnician, re upcoming dates, here's what I'm expecting:
• 10/27/17 Wayne State University presentation http://www.professionalabstracts.com/ectrims2017/iplanner/#/grid Credit tttav66 ihub poster: "Then scroll down to Friday the 27th, and look at the row at 14:00. You'll see "Parallel Session 14: Remyelination: from biology to clinical trials". Click that and you will see a list. Go down to Session 238 and click that. There you will see:" 238 - Sigma 1 receptor agonists as potential protective and reparative therapy in multiple sclerosis R.P. Lisak, L. Nedelkoska, J.A. Benjmains Neurology, Wayne State University School of Medicine, Detroit, MI, United States The complete abstract will be published on 15 October 2017.
• The Parkinson's and Disease Therapeutics Conference October 30, 2017 "The Parkinson's Disease Therapeutics Conference is The Michael J. Fox Foundation's annual scientific conference and the only one in the world focused exclusively on Parkinson's disease drug development." She has one of only 8 posters at this year's event: Veronica Francardo, PhD Lund University ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism https://www.michaeljfox.org/research/parkinsons-therapeutics-conference.html?navid=pd-therapeutics-conf
• 11/1-11/4/17 CTAD Boston LBP33: Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease
• Neuroscience 2017 Conference November 13, 2017 from 3-4p Topic: 370.07 / C20 - Efficacy of ANAVEX 2-73, a Sigma-1 receptor agonist, in the MECP2 mouse model of Rett syndrome; Authors: J. S. SPROUSE, N. REBOWE, D. KLAMER, C. MISSLING; Anavex Life Sci., New York, NY https://www.abstractsonline.com/pp8/#!/4376/presentation/16595
• Neuroscience 2017 Conference November 14, 2017 from 2-3p http://www.abstractsonline.com/pp8/#!/4376/presentation/28724 572.22 / S4 - ANAVEX 2-73, a clinical Alzheimer drug candidate, induces neurorestoration in experimental parkinsonism Authors *V. FRANCARDO1, F. BEZ1, J. S. SPROUSE2, C. MISSLING2, A. CENCI1; 1Lund Univ., Lund, Sweden; 2Anavex Life Sci., New York, NY "Conclusion: Our results reveal that ANA 2-73 ameliorates motor deficits in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts noticeable neurorestorative effects on the damaged nigrostriatal dopamine system. Further experiments are now ongoing to elucidate the mechanisms underlying these effects."
[Lastly, someone on the board had posted a link to another conference in Spain? in MAY 2018? that we'd copied/pasted the below abstract from Dr Francardo as well. However I can no longer find the link to the abstract/conference to cite the below, will need to reconfirm: "Using the same animal model of PD as in our previous study (i.e. intrastriatal 6-OHDA mouse model), we investigated the potential neurorestorative effects of ANAVEX 2-73, a compound with activity at both Sigma-1 and muscarinic receptors that is currently being tested in people affected by Alzheimer´s disease. Our results reveal that ANAVEX 2-73 is able to ameliorate parkinsonian motor symptoms in tests assessing spontaneous rotational activity and forelimb use asymmetry, and exerts neuroprotective/neurorestorative effects on the nigrostriatal dopamine system."
News 
Market Data 
Discover 
